))
Discontinuing DMTs in Patients with Stable Relapsing-remitting MS: When and How?
Manage episode 407345642 series 3559522
内容由European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis提供。所有播客内容（包括剧集、图形和播客描述）均由 European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Long term use of disease modifying treatments (DMTs) poses challenges in terms of safety and pharmacoeconomics, while preventing disability progression. As such, there is an ongoing debate on how long disease modifying treatments should be continued and if discontinuation should be considered in stable multiple sclerosis.
In this episode, Alan Thompson, Editor in Chief of the MS Journal, speaks with Gilles Edan, Professor of Clinical Neurology and chair of the Department of Neurosciences, University Hospital of Rennes; and Eva Strijbis, neurologist at the Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers.
35集单集
分享
